Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca 2+ balance protein levels

12Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Doxorubicin (DOX) causes long-term cardiomyopathy that is dependent on oxidative stress and contractility disorders. Tirapazamine (TP), an experimental adjuvant drug, passes the same red-ox transformation as DOX. The aim of the study was to evaluate an effect of tirapazamine on oxidative stress, contractile protein level, and cardiomyocyte necrosis in rats administered doxorubicin. Rats were intraperitoneally injected six times once a week with tirapazamine in two doses, 5 (5TP) and 10mg/kg (10TP), while doxorubicin was administered in dose 1.8mg/kg (DOX). Subsequent two groups received both drugs simultaneously (5TP+DOX and 10TP+DOX). Tirapazamine reduced heart lipid peroxidation and normalised RyR2 protein level altered by doxorubicin. There were no significant changes in GSH/GSSG ratio, total glutathione, cTnI, AST, and SERCA2 level between DOX and TP+DOX groups. Cardiomyocyte necrosis was observed in groups 10TP and 10TP+DOX. © 2012 Justyna Sliwinska et al.

Cite

CITATION STYLE

APA

Sliwinska, J., Dudka, J., Korga, A., Burdan, F., Matysiak, W., Jodlowska-Jedrych, B., … Dawidek-Pietryka, K. (2012). Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca 2+ balance protein levels. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2012/890826

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free